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Abstract 
Patient registries that document real-world clinical experience play an important role in 
cardiology as they complement the data from randomised controlled trials, provide valuable 
information on drug use and clinical outcomes, and evaluate to what extent guidelines are 
followed in practice.  
The Platelet Inhibition Registry in ACS EvalUation Study (PIRAEUS) project is an initiative of 
registry holders who are managing national or international registries observing patients with 
acute coronary syndromes (ACS). The aim of PIRAEUS is to systematically compare and 
combine available information/insights from various European ACS registries with a focus on 
P2Y12 inhibitors.  
The present publication introduces the 17 participating registries in narrative and tabular form, 
and describes which ACS groups and which dual antiplatelet therapies were investigated. It 
sets the basis for upcoming publications that will focus on effectiveness and safety of the 
antiplatelets used.  
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Registries, observational, acute coronary syndrome, ST-segment elevation myocardial 
infarction, non-ST-segment myocardial infarction, antithrombotics, P2Y12 inhibitors, 
clopidogrel, prasugrel, ticagrelor, methodology, real-world evidence. 
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BACKGROUND 
While rates of death due to cardiovascular diseases have declined over the past decades in 
both the United States and Europe, the attributable burden remains high.1, 2 Among these, 
acute coronary syndromes (ACS) represent the most frequent conditions in clinical practice. 
The spectrum comprises, based on electrocardiographic criteria and troponin elevation values, 
ST-segment elevation myocardial infarction (STEMI), non-ST-segment myocardial infarction 
(NSTEMI), and unstable angina (UA).3  
Percutaneous coronary intervention (PCI) has been established as standard for revascular-
ization in these patients, as the procedure relieves symptoms, shortens hospital stays, and 
improves prognosis.4, 5 The activation of platelets and their subsequent aggregation have a 
pivotal role in the propagation of arterial thrombosis and therefore platelets are the key 
therapeutic targets in the management of ACS.4, 5 Current guidelines place particular emphasis 
on dual antiplatelet therapy (DAPT) consisting of aspirin plus one of the P2Y12 receptor 
inhibitors, clopidogrel, prasugrel or ticagrelor, with the aim to reduce the risk of both acute 
ischaemic complications and recurrent atherothrombotic events.   
Overall, a substantial reduction in mortality and morbidity of ACS patients has been achieved 
through the introduction of new antithrombotic drugs, along with improved intervention 
techniques and optimisation of patient handling to achieve short symptom-to-intervention 
times, followed by prolonged long-term management of patients.6, 7  The multiple facets of 
current management in daily practice can only be assessed by means of large-scale registries, 
which explains why such studies have flourished in the last decade. 
There is no universal definition of a registry. The Agency for Healthcare Research and Quality 
(AHRQ), one of 12 agencies within the U.S. Department of Health and Human Services, 
describes a registry broadly as “an organised system that uses observational study methods to 
collect uniform data (clinical and other) to evaluate specified outcomes for a population 
defined by a particular disease, condition or exposure, and that serves one or more 
predetermined scientific, clinical, or policy purposes”.8   
Similar definitions and a number of guidelines have been issued by other organisations such as 
the International Epidemiological Association9, the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP)10 and others. 
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Real-world evidence (RWE) is a very important source of information on the efficacy and safety 
of clinical interventions. RWE has, however, major intrinsic limitations when analyzing clinical 
outcomes in relation to therapeutic management. In particular, potential unrecognized bias, 
even in the most clinically detailed registries, precludes drawing causal inferences between 
any given treatment and clinical outcomes. This has led the editors of the Heart Group Journals 
to publish a specific statement on the importance of matching language to the type of 
evidence gathered from observational studies compared with randomized clinical trials.11 As 
an illustrative example, the definitive statement “intervention reduced risk” (an active verb) 
should be reserved for randomised controlled trials (RCTs), while observational studies should 
use phrases such as, “lower risk was observed” or “there was a relationship with lower risk”.11 
Notwithstanding this caveat, registries, surveys and epidemiological studies have gained great 
importance in cardiology (as in other fields) as numerous examples show.12, 13 In contrast to  
RCTs, which enrol highly selected populations, registries usually recruit consecutive “all-comer 
patients” irrespective of concomitant diseases or co-medications. These patient groups are 
thus higher in medical complexity and risk. Sometimes differences are observed between 
outcome data from clinical trials and published RWE data. Event rates are likely to be higher in 
RWE settings due to the selective non-inclusion of the sickest patients in RCTs. Comparison 
between outcomes of controlled trials and observational trials allows researchers to check 
whether RCT findings in selected populations can be transferred to “real-world” patients (both 
in terms of baseline clinical characteristics and outcomes of treatment).14 Thus, registries 
provide a wealth of information to fill important gaps in the available evidence. Further, 
registries, in contrast to controlled trials, document the real utilisation of drugs (choice of 
drugs, dosages, switching) and procedures. They are particularly suitable for quality assurance, 
as individual centres can compare their results with other centres and with what is stated in 
guidelines. Although no conclusions on causal relations can be drawn, careful examination of 
registry data can provide valuable insight into optimal treatment in various clinical scenarios.  
The “Platelet inhibition Registry in ACS EvalUation Study” (PIREAUS) group is a European 
initiative of experts in cardiology who are managing national or international ACS registries. 
About twenty completed or ongoing registries have been set up in Europe to document clinical 
experience with ACS patients, many of whom undergo PCI and/or are treated with antiplatelet 
agents such as P2Y12-inhibitors. Individually, these registries are often too small to provide 
powerful datasets. The PIRAEUS working group therefore set out to integrate the wide array of 
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data generated by individual European ACS registries to derive a complete picture of various 
aspects of the management of this condition.  
The present overview introduces the participating registries in narrative and tabular form, and 
sets the basis for the upcoming publications that will focus on effectiveness (deaths and 
cardiac events) and safety (in particular, bleeding related to anticoagulation).  
 
METHODS 
The project was initiated during a meeting of pivotal members of the PIRAEUS group, who all 
are owners of or principal investigators in large ACS registries. They defined the criteria for 
including appropriate registries as: European multicentre or single-centre observational 
studies on real-life experience in the management of ACS; large unselected patient cohorts; 
percutaneous coronary intervention as main revascularisation strategy; data on management 
during initial hospitalisation for ACS available; follow-up data on outcomes (death, cardiac 
events, bleedings) available.  
Registries had to meet three further conditions: (1) the inclusion of patients from European 
countries, and (2) within the last 5 years, previous publication of data in peer-reviewed 
journals and/or reporting of unpublished data, with information on outcomes of drug 
treatment of patients with P2Y12 inhibitors at least until discharge from the hospital; (3) 
willingness of registry owners to take part in PIRAEUS and share data. A total of 17 registries 
that fulfilled all of the criteria were identified (overview in Table 1). 
Data on the registries were extracted in two steps: a large table shell was developed in 
cooperation with the various registry holders. First, based on recent publications and congress 
presentations, data on study setting, methodology, patient characteristics, medical treatment 
and outcomes in terms of effectiveness and safety were collected by independent reviewers 
with expertise in the field. In the second step, the table was sent to the individual registry 
holders with the request to double-check data, enter corrections, and, if indicated, add 
unpublished (more current) data.  
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DESCRIPTION OF THE ACS REGISTRIES 
 
APCI and ADAPT (Austria)  
The Austrian Acute PCI registry (APCI) is a nationwide, prospective, multicentre, observational 
registry of interventional reperfusion therapy in acute myocardial infarction. It was initiated in 
2005 to evaluate interventional therapy and determine predictors of successful treatment and 
in-hospital outcome in patients receiving coronary intervention in a real-world setting of AMI 
in Austria.15 
Currently, 19 of the total of 25 PCI centres with experience in acute PCI in Austria (at least 50 
cases per year) participate in the registry. 
Patients are eligible for documentation if they are admitted with AMI to one of the partici-
pating centres within 24 h (STEMI) or 72h (NSTEMI) of symptom onset.  
Collected data (using an internet-based questionnaire) include demographics, cardiac history 
with previous coronary intervention and previous MI, mode of admission, key time points and 
intervals to describe the event and intervention, the intervention itself together with drug 
treatment details, and the outcome.  
Three reports on the registry have been published to date, on primary PCI of STEMI in women 
16, on primary PCI of STEMI in Austria (results 2005-2007)15, and on clopidogrel pre-treatment 
in primary PCI for acute STEMI17. 
Since 2013, the ADAPT sub-registry (Austrian Dual Antiplatelet Therapy Registry) is 
prospectively enrolling patients to specifically address efficacy and safety of ticagrelor and 
prasugrel in real-world PCI in acute coronary syndromes and is still ongoing. Thus far, >2000 
patients have been enrolled. This study will involve a 1-year follow-up. Enrolment is expected 
to be completed by mid-2015. 
 
ALKK PCI (Germany) 
The Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK) coronary 
angiography and PCI registry” is a prospective multicentre registry that was initiated in 1992 as 
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an instrument to monitor quality control in participating hospitals in Germany. It contains all 
consecutive procedures of the participating hospitals on an intention-to-treat basis.18 Currently 
between 40-50 hospitals participate and contribute information on standardised 
questionnaires for central analysis on medical history, indication for the procedure, the 
adjunctive antithrombotic therapy, the procedure itself and the complications until hospital 
discharge. Between January 2006 and December 2013, a total of 70,000 consecutive patients 
with acute coronary syndromes (STEMI, NSTEMI) were included.19 
Over time, results of the ALKK PCI registry have been published in more than 40 publications. 
Topics included immediate multivessel PCI versus culprit lesion intervention in patients with 
acute myocardial infarction complicated by cardiogenic shock20, the use of drug-eluting stents 
in acute myocardial infarction with persistent STEMI21, and age-related differences in 
diagnosis, treatment and outcome of acute coronary syndromes and the use of new platelet 
inhibitors in PCI for STEMI and NSTEMI22.  
ATACS (Germany)  
The ATACS (Antithrombotic Therapy in patients with Acute Coronary Syndrome) registry is a 
sub-registry of the ALKK coronary angiography and PCI registry. For the ATACS registry in the 
30 participating hospitals between October 2009 and February 2013 specific information on 
timing and dosing of clopidogrel and prasugrel, risk factors for bleeding complications and 
timing and outcome of bleedings were added to the standard questionnaire. The registry 
focussed on ACS patients and the results of the STEMI patients scheduled for primary PCI, 
receiving a loading dose of either clopidogrel or prasugrel (n= 3291). Outcomes until hospital 
discharge were reported recently.23 Other results include the pre-PCI loading doses in 
NSTEMI.24 
AMIS-Plus (Switzerland) 
The Acute Myocardial Infarction in Switzerland (AMIS), in 2000 renamed to AMIS Plus after the 
extension to patients with unstable angina, is a prospective, multicentre national registry in 
Switzerland. It was initiated in 1997 to prospective collect real-life data on the whole spectrum 
of ACS patients.  
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Patients are eligible for documentation if they have a confirmed diagnosis of acute myocardial 
infarction (AMI), defined by characteristic symptoms and/or ECG changes and raised 
biomarker levels. Patients are categorised by STEMI and NSTEMI/UA diagnoses.25  
Participating hospitals include all types from regional to large tertiary centres. In 2010, out of 
106 hospitals in Switzerland treating ACS 76 temporarily or continuously contributed patients 
to AMIS Plus. According to an analysis of the Swiss Federal Statistic Office, participating and 
non-participating hospitals did not differ significantly in patient volume, skills or quality 
grading. Since 2005, a subset of hospitals also collects follow-up information on about half of 
the ACS patients via telephone interviews and questionnaires.25 
The data from the AMIS Plus registry are used to characterise patients with AMI and UA, 
record the examination and treatment strategies, assess compliance with guidelines, guide the 
optimisation of interventions, observe of changes over time as well as the economic 
consequences of treatment and the possible alternatives.25 So far, the registry collected 
blinded data from more than 49,000 patients.  
 
A pivotal paper on details and methods as well as on overview about the progress of AMIS Plus 
after 13 years’ conduct has been published.25 Further, more than 50 national and international 
publications based on the registry have reported manifold aspects of outcomes, for example 
most recently a propensity score-matched comparison of prasugrel and clopidogrel-treated 
patients with ACS undergoing PCI 26, 1-year outcomes of acute multivessel revascularisation in 
STEMI patients27, temporal trends over 15 years in the treatment of STEMI patients28, 
characteristics and outcome in ACS patients with and without established modifiable 
cardiovascular risk factors29, or derivation of the reproducibly accurate point-of-care risk 
(AMIS) stratification tool for the complete range of ACS, based on variables available at first 
patient contact.30 
 
Belgian STEMI registry  
The Belgian STEMI registry is a prospective observational multicentre study. The registry is an 
initiative from the Belgian Working Group on Acute Cardiology (BIWAC) and supported by the 
Belgian government and the Belgian College of Cardiologists. The registry started in January 
2007 and is ongoing.  
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All Belgian hospitals irrespective of size and care level are eligible for participation if they have 
an acute care facility; currently 72 hospitals contribute data. The registry focuses on the 
documentation of consecutive patients with (suspected) STEMI.  
Results of the cohort have been published including those on in-hospital mortality with focus 
on reperfusion treatment modalities31 and by hospital type32, gender effects 33, influence of 
renal function on outcomes 34, outcomes in patients aged 80 years and older 35, and inter-
hospital variation in length of hospital stay 36.  
 
BLITZ-4 (Italy) 
“Blitz-4 Qualita’” project started in 2009 with the support of the Italian Association of Hospital 
Cardiologists (ANMCO) and involved 163 Italian Coronary Care Units (CCUs) spread across the 
entire Italian territory. The goal of the project was to prospectively collect demographics, 
process of care and outcome measures among patients with ACS (STEMI or NSTEMI), to 
provide feedback to participating centers as well as specific interventions aimed at increasing 
compliance with the guidelines, and, ultimately, to improve the quality and standardization of 
myocardial infarction care. Blitz-4 included two phases of patient enrolment (from 15 
September to 30 November 2009 and from 15 February to 30 April 2010), each followed by 
feedback regarding the local performance, based on the measure of guideline-derived quality 
indicators. Only the CCUs with an expected case load of at least 20 patients with STEMI and 20 
patients with NSTEMI during each enrolment period were really involved in the project (163 
out of about 400): of them 83% had an interventional cardiology facility and 69% a 24/7 
catheter lab access. Patients with unstable angina were excluded from the study. 
Overall, 5854 patients with STEMI and 5852 patients with NSTEMI were consecutively enrolled. 
Data collection included pharmacological and non-pharmacological indicators of performance 
as well as measure of excess dose of antithrombotic drugs in eligible populations. Outcome 
measures during the in-hospital stay, at 30 days37 and at 6 months38 were also collected. 
CPU Registry (Germany) 
The German Chest Pain Unit (CPU) registry is a prospective multicentre registry in all parts of 
Germany. CPUs are an integral part of emergency cardiology services with the purpose to 
deliver quick and targeted identification of the origin of acute unclear chest pain. The German 
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Cardiac Society (DGK) defined obligatory minimal standards for CPUs, which include 24-hour 
catheterization and intervention facilities. As all certified CPUs serve as gate to a 
catheterization lab, referral to a CPU are a fast-track to coronary angiography and intervention 
if required.  
The German CP registry was set up in 2008 to internally and externally validate the medical 
care quality in the area of CPUs, including benchmark reports for general performance and 
risk-adjusted comparisons between centres. All types of hospitals, if certified as described, 
take part in this (ongoing) CPU registry.  
Patients admitted to a CPU in Germany prospectively and consecutively. All forms of ACS are 
documented as a part of this patient group. Data are collected during the hospital stay, and in 
addition, during telephone interview at 3 months after the event. Data are not audited or 
monitored.  
In a prospectively defined subgroup of patients with ACS, a 12-month follow-up was 
performed. This subgroup included 453 patients initially treated with prasugrel and a matched-
pair group of 453 patients treated with clopidogrel.39  
CZECH-2 (Czech Republic) 
CZECH-2 is a prospective multicentre, observational, regional registry study in the Czech 
Republic. It aims to provide epidemiologic data (incidence) on ACS as well as treatment and 
outcome data.  
A total of 28 regional hospitals without catheterization availability and 4 cardiocentres with a 
catheterization laboratory (thus, all hospitals being parts of well-established PCI networks) in 4 
counties in the South, North and West of the Czech Republic participated during the 2-month 
enrolment period between 1 October and 30 November 2012). This setup enabled to enrol all 
consecutive patients admitted during a given period to any existing hospital within a territory 
with well-defined population. 
Patients were eligible for enrolment if they had an admission diagnosis of STEMI, NSTEMI, UA, 
acute heart failure with known coronary artery disease, chest pain with suspected ACS, 
resuscitation in the prehospital phase, or another initial diagnosis confirmed as ACS during 
hospitalization.  
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A report on the incidence of suspected versus confirmed ACS (including incidence of STEMI, 
non-STEMI or UAP separately), patient characteristics, diagnostics and treatment patterns as 
well as 30-day outcomes with respect to mortality and major cardiovascular events have been 
reported recently.40  
 
DIOCLES (Spain) 
The Descripción de la Cardiopatía Isquémica en el Territorio Espanol (DIOCLES) study is a 
prospective, multicentre, observational study in Spain to identify the mortality and 
management of patients admitted for suspected acute coronary syndrome. It documents 
consecutive ACS patients. The study was performed between January and June 2012 in 44 
hospitals randomly selected, with 2557 patients documented at admission and after 6-month 
follow-up. 
Various health care levels are represented by stratified randomisation by type of institution 
(35% sites with a cardiologic or general critical care unit and interventional cardiology 
laboratory (type A site), 45% with a critical care unit without interventional cardiology 
laboratory (type B site), and 20% without a critical care unit (type C site).  
Patients were eligible for documentation if they were admitted for suspected ACS (STEMI, 
NSTEMI, unclassified ACS, or unstable angina) that was first managed at the participating site 
(except prehospital treatment or admission a few hours after primary PCI at another site). 
Informed consent was mandatory, but not required to analyse cases of in-hospital death. 
Patients were excluded if ACS was secondary to other processes, such as tachyarrhythmia, 
severe anaemia, or surgery; if they had been transferred from another site where they had 
been admitted for ACS.  
The characteristics of2557 ACS patients, their management and 6-month outcomes of the 
study have recently been published.41 
 
EPICOR (international) 
The “long-tErm follow-up of antithrombotic management Patterns In acute CORonary 
syndrome patients” study (EPICOR) is a prospective, multinational, observational study. 
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Between September 2010 and March 2011, it documented patients discharged after a 
hospitalization for an ACS with 2-year follow-up. A total of 555 hospitals (representing all types 
of care) in 20 countries from 4 pre-defined regions (Northern Europe, Southern Europe, 
Eastern Europe and Latin America) participated.  
Patients were eligible for documentation if they were hospitalised within 24 hours of onset of 
symptoms of the ACS event for the first time, had a final (discharge) diagnosis of STEMI, 
NSTEMI or unstable angina, and had survived the initial hospitalisation. Patients were not 
eligible to participate if their ACS was precipitated by or was a complication of surgery, trauma, 
or gastrointestinal bleeding, or post-PCI; if ACS occurred during hospitalization for other 
reasons; or if their life expectancy was <6 months. 
The aims of EPICOR are to describe the short- and long-term (2 years) antithrombotic 
management patterns (AMP, choice of antiplatelet and anticoagulant drugs, their 
combinations, dosing, timing, and continuation of use during hospitalization and after 
discharge) in patients hospitalised for ACS, and to evaluate potential differences in short- and 
long-term clinical outcomes, economic costs, and quality of life among different AMPs, alone 
and in combination with the different reperfusion and invasive strategies, in different clinical 
environments.42 The study focuses on patients who survived the initial hospitalization for ACS; 
thus, patients who died in hospital are not included in the study. 
A methods/design paper reported the distribution of patients by countries and diagnoses 
(n=10,568 patients).42 A number of subsequent papers reported international antithrombotic 
treatment patterns and opportunities for improvement of pre- and in-hospital care of ACS 
patients,43 predictors of 1-year mortality at hospital discharge after ACS together with a new 
risk score44, contemporary inter-hospital transfer patterns45, as well as local analyses for 
example on the German centres46. 
 
EYESHOT (Italy) 
The “EmploYEd antithrombotic therapies in patients with acute coronary Syndromes 
HOspitalised in iTalian cardiac care units” (EYESHOT) registry is a multicentre, observational, 
prospective, nationwide study in Italy. It aims at evaluating in-hospital use of antithrombotic 
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therapies in consecutive ACS patients admitted to Italian intensive cardiac care units (CCUs) 
during a three-week period. 
As opposed to the Italian BLITZ-4 project, the Italian Association of Hospital Cardiologists 
ANMCO invited all Italian hospitals to participate, including university teaching hospitals, 
general and regional hospitals, and private clinics with CCUs treating ACS patients. 203 CCUs 
enrolled consecutive patients in two waves (160 CCUs from 2 December until 22 December 
2013, and 43 CCUs from 27 January until 16 February 2014). 
Patients were eligible for documentation if they had STEMI or NSTEMI, which were defined by 
established electrocardiographic and laboratory criteria.  
 
The treatment patterns in 2585 ACS patients by AMI type, and independent predictors for the 
novel P2Y12 inhibitors (prasugrel/ticagrelor) prescription in association with aspirin at 
discharge from hospital were presented in a recent publication.47 In addition, a dedicated 
paper on antithrombotic therapies employed in ACS patients not receiving revascularization 
during the index admission48 and on the impact of use of risk score on guidelines adherence 49 
have been recently published. 
 
FAST-MI (France) 
The “French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction” (FAST-
MI) is a nationwide multicentre survey of the management and outcomes of consecutive 
patients hospitalised for acute myocardial infarction. It is part of a programme implementing 
nationwide one-month surveys carried out 5 years apart each, since 1995. The first FAST-MI 
survey per se was carried out in 2005, a second cohort was recruited in 2010, and a third 
cohort is due at the end of 2015.  
Patients were eligible for documentation if they had an acute myocardial infarction (STEMI and 
NSTEMI, but not unstable angina or iatrogenic AMI) and were admitted alive to the coronary 
care unit or intensive care unit within 48 hours of symptom onset. Patients who died very soon 
after admission and for whom cardiac markers were not measured were included if they had 
compatible signs or symptoms associated with typical ECG changes. Likewise, patients dying 
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very early, before they could give informed consent, were included in the database unless the 
next of kin objected. 
 All types of institutions were eligible for participation (i.e., university hospitals, public 
hospitals, military hospitals, or private clinics, with or without on-site catheterization 
facilities).50, 51 The latter 2 cohorts FAST-MI 2005 and 2010 were overseen by the French 
Society of Cardiology, and sponsored by industry grants. For the 2005 cohort, the 223 
participating centres represent 60% of all centres in France who treated patients with AMI at 
that time. Follow-up of the original cohort of patients was 5 years. 52 All-comers were included 
consecutively for one month, and diabetic patients were included during two months. A new 
cohort (FAST-MI 2010) has been accrued in 2010, with 213 participating centres (76% of 
French centres taking care of AMI patients).53, 54 All centres participated in the one-month 
survey, and voluntary centres could also include patients for up to one additional month.  
Design and methods of FAST-MI have been published in designated stand-alone publications. 
51, 53  Also, outcomes have been published extensively, including a comparison of thrombolysis 
followed by broad use of PCI with primary PCI for STEMI50, efficacy and safety of a standard 
versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of 
age55, clinical events as a function of proton pump inhibitor use, clopidogrel use, and 
cytochrome P450 2C19 genotype56, usefulness of fetuin-A and C-reactive protein 
concentrations for prediction of outcome57, comparison of low molecular weight heparin 
versus unfractionated heparin in terms of bleeding complications and one-year survival in the 
elderly58, comparison of acute MI patients with and without obstructive coronary lesions,59 
incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial 
infarction60, effect of coronary thrombus aspiration during primary PCI on 1-year survival, and 
5-year survival according to modalities of reperfusion therapy.52 
 
MINAP (England/Wales/Northern Ireland) 
The Myocardial Ischaemia National Audit Project (MINAP) is a national cohort study (registry) 
set up in 2000 which contains data from patients with an ACS admitted to all (230) National 
Health Service (NHS) hospital trusts in England and Wales, and more recently those in 
Northern Ireland.61 The registry aims at complete coverage of all ACS patients, regardless of 
where the patient is admitted within a hospital, though case ascertainment is incomplete. 
16 
For the primary purpose to provide hospitals with contemporary online analyses of their 
individual performance and comparisons with national aggregate data, MINAP uses a dataset, 
presently of 130 data items, that allows examination of pre-hospital and in-hospital care of all 
ACS. So, it follows the full pathway of care ACS from the onset of symptoms until hospital 
discharge, whether or not patients undergo a coronary intervention.  
Patients are eligible for documentation if on admission the diagnosis is of definite or probable 
myocardial infarction. The data application contains data validation processes including range 
and consistency checks. Since the start of the project more than 1.25 million cases have been 
documented, with a little over 80,000 cases of definite ACS (40% STEMI) being added each 
year.  
More than 40 publications have appeared from the registry, most recently mortality and 
missed opportunities along the pathway of care for STEMI a as national cohort study 62, on the 
association between older age and receipt of care and outcomes in patients with ACS 63, or 
age-dependent inequalities in improvements in mortality occur early after ACS 64. Additionally 
the registry has been used to inform national policy and local quality improvement initiatives. 
A report on hospital performance is made public each year65 and limited information appears 
on government web pages. Hospital specific mortality outcome data (for STEMI) appeared for 
the first time in the public report 2013/14. 
 
MULTIPRAC (international) 
The “MULTInational non-interventional study of patients with ST-segment Elevation 
Myocardial Infarction Treated with PRimary Angioplasty and Concomitant use of upstream 
antiplatelet therapy with prasugrel or clopidogrel” (MULTIPRAC) is a prospective open-label 
non-interventional study, performed between June 2011 and June 2013 in 25 large centres in 9 
countries.  
It is an expert study, as centres were selected for participation if they performed at least 100 
primary PCIs per year, were part of an admission network, and had a clearly defined pre-
hospital treatment practice with thienopyridines in place. Patients were eligible if they had a 
STEMI diagnosis, and received upstream (pre-hospital) prasugrel or clopidogrel loading dose 
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(LD, i.e. 300/600 mg for clopidogrel or 60 mg for prasugrel) immediately after the diagnosis 
and prior to/during ambulance transport to a cathlab hospital for primary PCI.  
The study focuses on the use patterns and effectiveness of dual antiplatelet therapy (DAPT) 
initiated in the pre-hospital phase and mainly offers comparative data on DAPT based on 
prasugrel or clopidogrel. A total of 2053 STEMI patients were included and followed up for 1 
year.  
As of today, two major publications have emerged from this study, which describe the 
mortality and safety outcomes during the initial hospitalisation period,66 and mortality after 
the one-year follow-up period, respectively (paper submitted).  
SCAAR (Sweden) 
The SCAAR (Swedish Coronary Angiography and Angioplasty Registry) is a prospective 
multicentre registry, with audit and monitoring procedures. Since 1990, it documents all 
consecutive coronary angiographies and PCI procedures performed in Sweden.67 The registry 
covers all regions of Sweden and all 29 hospitals with a catheterization laboratory and enrols 
all patients.  
Patients are eligible for inclusion, if they have an indication for angiography owing to stable 
coronary artery disease, acute coronary syndrome (unstable angina, NSTEMI and STEMI) or 
other indications (e.g. cardiac arrest, heart failure, arrhythmias).  
The SCAAR registry is part of the SWEDEHEART registry collaboration which includes other 
databases like RIKS-HIA (the national Swedish cardiac intensive care registry), SEPHIA (follow-
up after acute coronary syndromes), the national cardiothoracic surgery registry and the 
national TAVI registry. Data from these other registries can be merged with SCAAR in order to 
add additional information. Data from the Swedish National Population Registry is linked with 
SCAAR using personal identification numbers as permitted by the local laws to enable regular 
online updates on mortality in all patients.  
Data from SCAAR are reported annually.68 In addition, over 20 publications have described 
results, e.g. on treatment patterns and outcomes in patients undergoing PCI treated with 
prasugrel or clopidogrel in 2010-2011 69, current treatment and outcome of coronary in-stent 
restenosis 70, population trends in PCI over 2 decades71, or experience with various types of 
stents or balloons72-75.  
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SPUM ACS (Switzerland) 
The SPUM-ACS (Special Program University Medicine-Acute Coronary Syndromes) research 
network collects data since 2009 on a prospective cohort of patients hospitalised for an ACS in 
4 university medical centres in Switzerland (Bern, Geneva, Lausanne and Zurich). This 
cooperative project focuses on the role of inflammation in ACS and its role in the 
pathogenesis, diagnosis, therapy, and prevention of ACS.76  
Patients are eligible for documentation if they are hospitalised within 72 hours after pain onset 
with a main diagnosis of ACS. The final ACS diagnosis is classified as STEMI, NSTEMI or UA.  
In Cohort 1 (recruited between 9/2009 and 10/2012), as per protocol and according to the ESC 
Guidelines, patients were treated with dual antiplatelet therapy (DAPT) after primary 
percutaneous coronary intervention (PCI) with clopidogrel (NSTEMI, STEMI <60 kg or >75 years 
or history of TIA or stroke) or prasugrel (other STEMIs). Bleeding and outcome were assessed 
prospectively by an independent event adjudication committee.77 
As part of the SPUM ACS subproject, the ELIPS programme (Multi-dimEnsionaL prevention 
Program after Acute coronary Syndrome) aims at improving quality of care and adherence to 
guidelines of patients admitted to hospital with Acute Coronary Syndrome (ACS) 
(https://clinicaltrials.gov/ct2/show/NCT01075867). This program reported reasons for non-
prescription of recommended medications in ACS78 and showed that discontinuation of 
recommended therapies after ACS differed per class of medication.79 Moreover, this 
subproject investigated how application of the new 2013 AHA/ACC guidelines would change 
the proportion of patients achieving recommended lipid targets 1 year after ACS.80 
A multimodality intracoronary imaging project assessed the effects of long-term high-intensity 
statin therapy on plaque burden, composition, and phenotype in non-infarct-related arteries 
of STEMI patients undergoing PCI.81 
 
UK STEMI Newcastle 
The Newcastle STEMI dataset is not a typical registry, but a retrospective analysis of 
prospectively collected data of the Freeman Hospital, Newcastle-upon-Tyne, in United 
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Kingdom. This is a regional tertiary centre serving a population of approximately 2 million and 
performing over 850 primary PCI cases per year. A single report has been issued to date on a 
total of 1668 patients not older than 75 years and over 60 kg in weight, who underwent 
primary PCI for STEMI between March 2008 and June 2011, comparing characteristics and 1-
year mortality of consecutive patients.82 
 
SUMMARY AND DISCUSSION 
Observational studies including the ACS registries described in this overview are valuable in 
that they provide information about the course of disease, patient characteristics, patterns 
and changes in treatment approaches (in line with or deviating from guidelines), and outcomes 
in individuals managed under real-life conditions.  
Only aggregated data are used in the PIRAEUS project, since no individual patient information 
could be exchanged between studies owing to data protection standards. While it is tempting 
to combine all data into one large database for extensive statistical analysis, the group 
members acknowledge that this strategy is accompanied by many challenges. One important 
caveat is that data have been collected for different purposes and in different ways. Thus, it 
must be carefully considered which data may and which may not be combined. In certain 
cases, the data from some registries may be compiled for analysis, but only when deemed 
appropriate.  
Overall, the PIRAEUS working group concluded that addressing the same clinical question in 
separate analyses of data obtained with different methodologies may provide a better idea 
than analysis of huge numbers, but with many caveats.  
Another important consideration is whether adjusted or unadjusted data should be presented. 
The PIRAEUS working group reached consensus that it is often inappropriate to provide 
unadjusted data, as the registry data are inevitably the result of confounding by indication. For 
instance, a large difference in age and risk profile is commonly seen between patients treated 
with clopidogrel and prasugrel. If in specific situations, adjusting is possible and meaningful, 
data will be presented as such in the upcoming review papers.  
We present similarities, but also, as expected, substantial differences in many aspects of the 
17 ACS registries that were compared. Only the EPICOR registry (worldwide, in 20 countries) 
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and the MULTIPRAC registry (9 countries) are multinational projects, while all others focus on 
one country or parts of one country, or even on one hospital. The number of centres also 
varied widely (from 1 in Newcastle to 555 in EPICOR), as did the number of patients (from 
1,221 in the Austrian registry to > 1.25 million in the MINAP cohort). The latter registry plays a 
particularly important role as documentation of all patients with ACS is mandatory in England 
and Wales. The same is true for the ALKK registry, since reimbursement of the procedure is 
linked to this registry. 
Some studies included patients over a short time period (“inclusion waves”) to provide a 
snapshot of current practice (e.g. EYESHOT, CZECH-2). Others, which are more typical 
registries, have been enrolling patients for over a decade or longer (ALKK, MINAP, etc.) and 
thus can provide sentinel analyses. Consecutive inclusion of suitable patients was explicitly 
stated in all studies (with the exception of AMIS-Plus and the German CPU registry). This 
constitutes an important attribute for a study to achieve representativeness of the 
documented cohort and to avoid selection bias.12, 14  
Almost all registries included both STEMI and NSTEMI ACS patients, with the exception of 
MULTIPRAC and the Belgian registry, which focused on STEMI only. All registries provide data 
on mortality at least for the in-hospital phase, and a subset of 8 registries allows analyses by 
P2Y12 inhibitor treatment given for ACS.  
About half of the registries were funded by industry (with unrestricted grants or assuming the 
sponsor role). Therefore, when interpreting the outcomes of registries, a number of 
methodological considerations apply to this study class. Different sources of bias and 
confounding can obscure any true causal association.83 Clinical decisions of the treating 
physicians may assign patients to different drugs based on disease severity, disease duration, 
presence of comorbidities, and other factors. This can potentially introduce allocation or 
channelling bias and confound the association between treatment and outcomes. Selection 
processes with regard to centres (participants with higher levels of expertise) and patients 
(participants probably more adherent to therapy) may limit the transferability of findings to 
the overall healthcare system.  
A major strength of those registries that are maintained long-term, such as AMIS-plus, MINAP 
and the ALKK registry, lies in the continuity of data collection, which allows analyses of changes 
over time. As guideline recommendations may not be durable owing to constantly improving  
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medical knowledge84, registries open the unique opportunity to assess the timely 
implementation of necessary changes in medical or interventional treatments.25 
The various ACS registries presented in this overview have provided detailed insights on the 
management and outcomes of ACS patients. These registries will, both as individual projects 
and also in the context of PIRAEUS, contribute to the further improvement of treatment for 
these patients.
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Table 1. Overview on ACS studies  
Registry Acronym APCI / ADAPT ALKK-PCI /ATACS AMIS Plus APTOR Belgian STEMI BLITZ-4 CPU CZECH-2 DIOCLES 
Full registry title Austrian Acute PCI 
Registry/ Austrian Dual 
Antiplatelet Therapy 
Registry 
Arbeitsgemeinschaft der 
Leitenden 
Krankenhausärzte 
Acute Myocardial 
Infarction in Switzerland 
Antiplatelet Therapy 
Observational Registry 
Belgian STEMI registry  BLITZ 4 Qualità 
campaign 
Chest Pain Unit Registry  Descripción de la Cardiopatía 
Isquémica en el Territorio 
Espanol  
ClinicalTrials.gov identifier   NCT01305785  NCT00727623     
Settings          
Countries Austria Germany Switzerland International  Belgium Italy Germany Czech Republic Spain 
Number of centres 19 / 9 > 40 83 122 72 163 38 CPUs 32 44 
Type of centre capable to perform 
Primary PCI  
regional, municipal, 
large tertiary 
regional, municipal, large 
tertiary  
teaching and non-
teaching hospitals  
all types high volume high volume regional hospitals, 
cardiocenters 
all types, randomly selected 
Patient number overall, n 23,000/ >2,000 > 15,000 per year  49,699 4148 200/month  11,706 11,656 1221 2557  
Methodology          
Study population Patients with AMI who 
undergo invasive 
treatment <24 h after 
onset of symptoms in 
STEMI or <72 h in 
NSTEMI 
All patients undergoing 
PCI for an AMI within 24 
h after symptom onset  
Patients admitted with 
acute coronary syndromes 
to hospitals in Switzerland 
Patients with STEMI, 
NSTEMI or UA 
Patients with acute 
STEMI admitted in 
Belgian hospitals 
Patients with STEMI and 
NSTEMI 
Patients with acute 
chest pain  
Patients admitted 
for suspected ACS 
Patients admitted for suspected 
ACS 
Exclusion criteria n.r. n.r. None  Acute myocardial 
infarction as an acute 
complication of 
coronary intervention 
Unstable Angina n.r. n.r. ACS secondary to other 
processes; patient transferred 
from another site; recent 
participation in clinical trial 
Primary study aim To assess efficacy and 
safety of new P2Y12 
antagonists (prasugrel 
and ticagrelor) in 
clinical practice of 
primary PCI for STEMI 
and early invasive/ 
urgent treatment 
strategy for NSTEMI  
Overall outcomes, quality 
control 
All cause death Country-specific 
patterns of health care 
used in ACS patient 
management. 
All cause mortality To assess and promote 
compliance of Italian 
CCUs with evidence-
based guidelines for the 
management of acute 
MI 
The validation of the 
quality of care, incl. 
benchmark reports and 
risk-adjusted 
comparisons in a 
prospective fashion 
To assess the 
incidence, treatment 
strategies, and 
outcomes of ACS for 
a well-defined 
population within a 
well-established 
network of PCI and 
non-PCI centres 
To identify the current mortality 
and management of patients 
admitted for 
suspected ACS in Spain 
Inclusion period 01/2005 – ongoing  
01/2013 – ongoing 
1994 – ongoing  1997 - ongoing  01/ 2007- 10/ 2007 
04/ 2008 - 05/ 2009 
01/2007 - ongoing 09/2009 - 11/2009 and 
02/2010 - 04/2010 
12/2008 - 08/2011 10/2012-11/2012 01/2012 - 06/2012 
Prospective study  yes yes Yes yes yes yes yes yes yes 
Duration of follow-up 1 vear (ADPAPT) in-hospital phase  1 year in hospital and 30 days 6 months 12 months  6 months 
Consecutive enrolment yes yes no yes yes yes no yes yes 
Monitoring  no yes yes no 5% data check No 10 % data check no yes (in 8 centres) 
Comparison          
STEMI / NSTEMI ● /● ● /● ● /● ● /● ● / no ● /● ● /● ● /● ● /● 
Prasugrel / Clopidogrel 
/Ticagrelor 
● /● / ● ● /● /● ● /● /● no /● /no ● /● /● 
Data available (from 
1/1/2015) 
no /● /no ● /● /● no /● / no ● /● /no 
Funding          
 Austrian Society of 
Cardiology 
ALKK: public funding 
ATACS substudy: Lilly 
Astra-Zeneca, Bayer-
Schering, Biotronik, Daiichi-
Sankyo/Lilly, Invatec, A. 
Menarini, Medtronic, St. 
Jude Medical, Abbott, 
Biosensors, BMS, GSK, J & 
J, MSD-Chibret, Essex, 
Novartis, Pfizer, Sanofi-
Aventis, Servier, SPSS, 
Takeda  
Elli Lilly and Daiichi 
Sankyo 
Ministry of Public 
Health of the Belgian 
government. 
MSD German Cardiac Society  Daiichi-Sankyo  
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Table 1. (continued) 
Registry Acronym EPICOR EYESHOT FAST-MI 2010 MINAP MULTIPRAC SCAAR SPUM-ACS STEMI Newcastle  
Full registry title long-tErm follow-up of 
antithrombotic 
management Patterns 
In acute CORonary 
syndrome patients 
EmploYEd 
antithrombotic 
therapies in patients 
with acute coronary 
Syndromes HOspitalised 
in iTalian cardiac care 
units 
French Registry of Acute 
ST-Elevation and Non-
ST-Elevation Myocardial 
Infarction 
Myocardial Ischaemia 
National Audit Project  
MULTInational non-
interventional study of 
patients with STEMI 
infarction Treated with 
PRimary Angioplasty and 
Concomitant use of 
upstream antiplatelet 
therapy with prasugrel 
or clopidogrel 
Swedish Coronary 
Angiography and 
Angioplasty Registry 
Special Program 
University Medicine-
Acute Coronary 
Syndromes 
 
ClinicalTrials.gov identifier NCT01171404 NCT02015624 NCT01237418 none none  NCT01000701  
Settings         
Countries Europe and Latin 
America, 20 countries 
Italy France England,Wales and 
Northern Ireland 
9 European countries Sweden Switzerland UK 
Number of centres 555 203 213 ca. 230  25 30 4  1 
Type of centre all types all types all types all types high volume all hospitals with PCI 
facility  
academic  tertiary 
Patient number overall, n 10,568 2585 4069 > 1.25 million 2053 34,363 2286 1688 
Methodology         
Study population Patients hospitalised 
within 24 hours of 
onset of symptoms 
and diagnosed UA, 
STEMI or NSTEMI 
Patients with ACS 
admitted to cardiac care 
units (STEMI and 
NSTEMI) 
Admitted patients in a 
Unit of Coronary 
Intensive Care (USIC) for 
AMI (STEMI or NSTEMI) 
Patients with admission 
diagnosis of definite or 
probable STEMI or of 
NSTEMI 
STEMI patients. Patients 
were grouped according 
to adherence to the 
initially prescribed 
thienopyridine 
ACS-PCI patients on 
prasugrel or clopidogrel 
Patients presenting with 
ACS 
Patients who underwent 
PPCI for STEMI divided 
in clopidogrel and 
prasugrel group 
Exclusion criteria Presence of any 
condition/ 
circumstance 
significantly limiting 
the complete follow 
up of the patient; 
current participation 
in a clinical trial 
Those not giving 
informed consent 
AMI occurring within the 
48 hours after any 
therapeutic 
intervention; diagnostic 
of AMI not confirmed 
ACS that is not Type 1 
myocardial infarction. 
(Type 3 myocardial 
infarction – sudden 
death – can be included 
if an ECG showed 
evidence of AMI) 
Ticagrelor pre-loaded 
patients as ticagrelor 
was not marketed when 
the protocol was 
developed 
n.r. Severe physical disability, 
dementia or less than 1 
year of life expectancy 
(for non-cardiac reasons) 
Patients with age ≥75 
years, weight<60 kg, 
history of 
cerebrovascular 
accident, TIA’s, active 
bleeding, known hepatic 
impairment 
Primary study aim Characterisation of 
antithrombotic 
management patterns, 
in relation with clinical 
outcomes (ischemic 
and bleeding), 
economic costs, and 
quality of life  
To obtain a full set of 
data on different 
antithrombotic 
therapies routinely used 
in ACS patients with 
different risk profiles 
and undergoing 
different therapeutic 
strategies 
To describe patient 
characteristics and 
management patterns, 
in relation with all-cause 
mortality and other 
clinical outcomes at 
each follow-up period 
(up to 10 years) 
To audit care of ACS 
against standards 
relating to timeliness of 
reperfusion and use of 
secondary prevention 
medication 
To gain insights into the 
use patterns and 
outcomes of pre- 
hospital DAPT initiation 
with prasugrel or 
clopidogrel 
To compare the 
incidence rates of 
SCAAR-defined major or 
minor bleeding between 
prasugrel/clopidogrel) 
treated patients with 
ACS undergoing PCI 
during the index 
hospitalisation 
MACE in all patients, 
defined as composite of 
death, cardiac death, 
myocardial infarction, 
ischemia-driven 
revascularization, 
definitive stent 
thrombosis, TIA or stroke 
All-cause mortality; To 
assess prasugrel versus 
clopidogrel mortality 
outcomes in patients 
admitted with STEMI 
undergoing PPCI 
Inclusion period 01/2010 - 03/2011 12/2013 and 01-02/2014 10-11/2010 10/2000 – present day 06/2011 - 06/2013 05/2010 - 04/2013 09/2009 - 10/2012 03/2008 -12/2009 
Prospective study  yes yes yes yes yes yes Yes no  
Duration of follow-up 2 years  10 years Linked vital status 
available  
1 year  1 year   
Consecutive enrolment yes yes yes yes yes yes yes yes 
Monitoring  yes No yes yes yes (offsite) no no  no 
Comparison         
STEMI / NSTEMI ● /●  ● /● ● /● ● /● ● / no ● /● ● /● ● / no 
Prasugrel / Clopidogrel 
/Ticagrelor 
● /● /no ● /● /● ● /● /no no /● /no ● /● /● ● /● ● /● /● ● /● 
Funding         
 AstraZeneca Heart Care Foundation; 
Unrestricted grant by 
AstraZeneca Italy 
Registry of the French 
Society of Cardiology. 
Unrestricted grants from 
MSD, AstraZeneca, 
Daiichi-Sankyo and Eli-
Lilly, GSK, Novartis, 
Sanofi 
NHS via Health Quality 
Improvement 
Partnership (HQIP). 
Daiichi Sankyo and Eli 
Lilly  
Swedish Health 
Authorities independent 
of commercial funding; 
publication support by 
Eli Lilly 
Swiss National Science 
Foundation and 
additional educational 
grants by Astra- Zeneca, 
Biosensors, Eli Lilly, 
Biotronik, MSD, St. Jude 
Medical. 
No specific funding 
Table 1 legend  
Symbols   ● = information is available. - = information is not available.  
1) Dutch Trial Register NTR3704.  
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